By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile



29 Emmons Drive
Suite C-10
Princeton  New Jersey  08540  U.S.A.
Phone: 609-538-8200 Fax: 609-452-6467


Company News
Soligenix (SNGX) Announces Publication Successfully Demonstrating Enhanced Immunogenicity Of Its Heat-Stable Anthrax Vaccine 1/29/2015 8:00:08 AM
FDA Grants Soligenix (SNGX) "Fast Track" Designation For SGX301 For The First-Line Treatment Of Cutaneous T-Cell Lymphoma 1/7/2015 7:34:09 AM
Soligenix (SNGX) Announces Positive Preliminary Nonclinical Results In Macrophage Activation Syndrome 1/5/2015 7:30:45 AM
Soligenix (SNGX) Announces Publication of Combination Ricin/Anthrax Vaccine Data 12/29/2014 7:38:51 AM
Soligenix (SNGX) Announces Closing Of Public Offering Of Units 12/24/2014 9:57:58 AM
Soligenix (SNGX) Announces Pricing Of Public Offering Of Units 12/19/2014 8:40:46 AM
Soligenix (SNGX) Receives $617,000 In Non-Dilutive Financing From New Jersey's Technology Business Tax Certificate Transfer Program 12/11/2014 7:19:54 AM
Soligenix (SNGX) Appoints Oreola Donini, PhD, As Chief Scientific Officer 12/10/2014 7:34:29 AM
Soligenix (SNGX) Announces Formation Of Cutaneous T-Cell Lymphoma Medical Advisory Board 11/17/2014 11:51:57 AM
Soligenix (SNGX) Reports Third Quarter 2014 Financial Results, Highlighted With The Acquisition Of SGX301, Synthetic Hypericin, For The Treatment Of Cutaneous T-Cell Lymphoma 11/10/2014 8:47:54 AM